Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

of

病理-IHC免疫組織染色 Slide 1 病理-IHC免疫組織染色 Slide 2 病理-IHC免疫組織染色 Slide 3 病理-IHC免疫組織染色 Slide 4 病理-IHC免疫組織染色 Slide 5 病理-IHC免疫組織染色 Slide 6 病理-IHC免疫組織染色 Slide 7 病理-IHC免疫組織染色 Slide 8 病理-IHC免疫組織染色 Slide 9 病理-IHC免疫組織染色 Slide 10 病理-IHC免疫組織染色 Slide 11 病理-IHC免疫組織染色 Slide 12 病理-IHC免疫組織染色 Slide 13 病理-IHC免疫組織染色 Slide 14 病理-IHC免疫組織染色 Slide 15 病理-IHC免疫組織染色 Slide 16 病理-IHC免疫組織染色 Slide 17 病理-IHC免疫組織染色 Slide 18
Upcoming SlideShare
南洋商报 - 金鹰奖巡回讲座槟城站 Nanyang Golden Eagle Awards Presentation
Next

30 Likes

Share

病理-IHC免疫組織染色

附上credit後可分享使用

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

病理-IHC免疫組織染色

  1. 1. Gem Wu 吳懷玨 整理 2017/11/3 【病理】 免疫組織化學染色 Immunohistochemistry (IHC)
  2. 2. 看病理報告,完全不知道在說什麼,怎麼辦? “CK7-/CK20+, TTF1-, CK17+…”
  3. 3. Pathologist’s H&E is like the clinician’s H&P Special studies like IHC could be performed
  4. 4. Purpose of IHC Purpose 目的 Example Classification of tumors 區分腫瘤 carcinoma vs. lymphoma B cell vs. T cell lymphoma in situ lesions vs. invasive carcinomas 原位癌 或 侵襲癌 myoepithelial markers in breast cancers basal cell markers in prostate Prognostic factors 預後因子 Ki-67 in glioblastomas (GBM) Predictive factors for specific therapy 標靶治療效果預測 c-KIT ER, PR, HER2/neu Identification of extracellular material 胞外物質 β-2 microglobulin amyloid Identification of infectious agents 傳染性物質 CMV or HSV [整理自: Susan Lester, Manual of Surgical Pathology 3e]
  5. 5. IHC applications -1 Application Tumor markers Histological typing Carcinoma Cytokeratin Sarcoma Vimentin Glial tumor GFAP Melanoma HMB-45, Melan-A Lymphoma LCA Differentiation Sarcoma Liposarcoma S-100 Angiosarcoma CD31 factor VIII Leiomyo- sarcoma SMA Rhabdomyo- sarcoma Desmin [Note from Ming-Yuan Lee, M.D.’s Lecture] Application Tumor/site Markers Organ specific Thyroid Thyroglobulin prostate PSA Lung, thyroid TTF-1 Sub- classification B-cell CD20, CD79a T-cell CD3, CD5, CD43 NK cell CD56 Myeloid series MPO Infectious disease - CMV Lung PJP
  6. 6. IHC applications -2 Application Tumor markers Secretion or tumor products Adenocarcinoma CEA Neuroendocrine tumor Synaptophysin, insulin, gastrin Breast tumor BRST-2 HCC α-fetoprotein, Hepar-1 Choriocarcinoma β-HCG Yolk sac tumor or embryonal carcinoma α-fetoprotein Biological factors for prognostic values (Proliferation index) Ki-67 (anti-apoptotic factor) Bcl-2 (Poor prognosis) Her2 [Note from Ming-Yuan Lee, M.D.’s Lecture] Application Treatment marker s Therapy Tamoxifen ER/PR Herceptin HER2 Gleevec CD117 Erlotinib (Tarceva®) EGFR Pem- brolizumab PD-L1 不同的organ, standard不同 Lymphoma 50% Ki-67+可能只是moderate, 但breast可能就是high
  7. 7. Tumor sites 各別來看看不同地方的carcinoma可能會有哪些IHC
  8. 8. Carcinoma: CK7, CK20 CK7+ CK20+ Lung adenoCA Breast ductal, lobular CA Ovary, uterus, cervix colorectal adenoCA CK7+/CK20+ Transitional cell CA Pancreatic cancer cholangiocarcinoma CK7-/CK20- SqCC (lung, HEENT), lung Small cell CA, HCC, RCC, prostate, adrenal cortical CA thyroid Ligament of Treitz
  9. 9. Organ specific markers of carcinoma Breast Cancer – IHC有助規劃Treatment IHC result ER/PR HER2/neu Positive 70-80% 15-20% Borderline 5-10% 25-35% Negative 20-30% 70% [來自: Susan Lester, Manual of Surgical Pathology 3e] HER2/neu+ → 可用Herceptin治療 ↓ HER2/neu+用IHC(左)與ISH(右) Other markers: (如果不確定可以三個一起染) GCDFP-15, mammaglobin, GATA3… [Arch Pathol Lab Med. 2016;140:508–523; doi: 10.5858/arpa.2015-0173-CP)]
  10. 10. Organ specific markers of carcinoma Lung Cancer – IHC分辨不同類型 tumor CK7 CK20 TTF-1 P63 Chromogranin Adenocarcinoma 90+% 10-40% 60-90% 10-40% <10% Bronchioloalveolar carcinoma — nonmucinous 90+% 10-40% 60-90% 60-90% <10% Bronchioloalveolar carcinoma — mucinous 60-90% 60-90% 10-40% <10% Squamous cell carcinoma 10-40% <10% <10% 90+% <10% Large cell carcinoma 60-90% 10-40% 40-60% 40-60% <10% Small cell carcinoma 10-40% <10% 90+% <10% 40-60% Carcinoid tumor 40-60% <10% 10-40% <10% 90+% Metastatic colon carcinoma 90+% 10-40% <10% <10% <10% Metastatic breast carcinoma 90+% <10% <10% <10% <10% 通常會染TTF-1來確認lung origin,但總有些例外… [整理自: Susan Lester, Manual of Surgical Pathology 3e] Neuroendocrine tumor marker
  11. 11. Organ specific markers of carcinoma GI tract Cancer v. GYN cancer – 確認origin CDX2 is expressed in virtually 100% of colorectal adenocarcinomas. (除了MSI – microsatellite unstable genotype外) tumor CK7 CK20 MUC2 CDX2 WT-1 Stomach 60-90% 40-60% 40-60% 40-60% 40-60% pancreas 90+% 60-90% 90+% 40-60% 40-60% appendix 10-40% 90+% 90+% 90+% - Colon <10% 90+% 60-90% 90+% 60-90% Uterus 90+% 10-40% <10% 10-40% 40-60% Ovary, serous 90+% 10-40% 10-40% 40-60% 60-90% Ovary, mucinous 90+% 60-90% 10-40% 40-60% 10-40% Breast, no special type (NST) 90+% <10% 10-40% <10% 10-40% Breast, mucinous 90+% 10-40% 90+% - 60-90% [整理自: Susan Lester, Manual of Surgical Pathology 3e] 1 2 3 4 5 6 PAX-8是Müllerian duct轉錄因子,因此許多GYN tumor會表現,也可以此區別mets的breast CA v. primary
  12. 12. Organ specific markers of carcinoma Liver Cancer – 區分primary或metastasis Hep-Par 1 Ab, arginase-1 比傳統的 α-FP更sensitive與specific for HCC [圖來自: Susan Lester, Manual of Surgical Pathology 3e] Hepatoplastoma Cholangiocarcinoma ? ?CK7+, AE1/AE3+, keratin HMW+ 一般來說,liver primary cancer會有CAM5.2+, CK20-, CEA+ CD10+ cirrhosis (65-90%) ↓ HBV+ (50%) α-FP+, HEP+ CDX2+ HEP+ [Arch Pathol Lab Med. 2016;140:508–523; doi: 10.5858/arpa.2015-0173-CP)]
  13. 13. Other markers for carcinomas Prostate CA (NKX3.1) (PSA) TCC (GATA3) (Uroplakin) (p63, p40) RCC (PAX2) (PAX8) Thyroid papillary, follicular CA (Thyroglobulin) (PAX8) Most thyroid CA (TTF-1) adrenal CA (inhibin-α) (Melan-A) (Steroidogenic factor 1) SqCC (not organ specific) (p63+, p40+) (CK5)[Arch Pathol Lab Med. 2016;140:508–523; doi: 10.5858/arpa.2015-0173-CP)]
  14. 14. 一些小練習 要開始囉
  15. 15. Case 1 • Ex-smoker • Biopsy from left lower lobe of lung • w/ Hx of biopsy proven colon CA • Dx? CK20+++H&E CDX2+++ TTF1- (CK7-) [Arch Pathol Lab Med. 2016;140:508–523; doi: 10.5858/arpa.2015-0173-CP)]
  16. 16. [CASE2] 63M, no known primary carcinoma, CCx cervical lymphadenopathy, this is the result of FNA of the node: CK7-, CK20-, TTF1-, CDX2-, PSA+++, Villin-. Dx? [CASE3] 73F, hx hysterectomy for unknown reason, CCx retroperitoneal lymphadenopathy, image showed left pelvic sidewall mass probably residual ovary. this is the FNA result: ER++, WT++, PAX+++, CK7+++, CK20-, GATA3-, CDX2-, p63-. Dx? [Arch Pathol Lab Med. 2016;140:508–523; doi: 10.5858/arpa.2015-0173-CP)]
  17. 17. Lymphoma太難QAQ 請更專業的來吧…
  18. 18. 最後幾點原則 1. 看不懂報告,自己查資料也不懂的話,還是要請教病理專業! 2. IHC不是絕對,positive與negative的出現也有其機率,不能妄 下診斷。 3. 遇到奇怪的marker表現,或異常不表現,還是可以去survey一 下其他器官。小心駛得萬年船。
  • dearjupiter

    Sep. 9, 2020
  • cpyupath

    May. 3, 2020
  • WinneWu

    Dec. 27, 2019
  • lin0927

    Dec. 25, 2019
  • MeiFengLee1

    Nov. 12, 2019
  • ssusera75f58

    Jun. 23, 2019
  • ssuseraf3efc

    May. 18, 2019
  • ssuser3869df

    Feb. 14, 2019
  • PeikaiWu1

    Oct. 2, 2018
  • chow2300

    Jun. 25, 2018
  • AjmmDamh

    May. 29, 2018
  • artiagarwal10

    May. 10, 2018
  • YuehChanLee

    Mar. 21, 2018
  • takeshili3

    Jan. 21, 2018
  • rechard4061

    Dec. 24, 2017
  • ssuser5d6bf9

    Dec. 23, 2017
  • aguswibowo38

    Nov. 14, 2017
  • tonyshell

    Nov. 11, 2017
  • GinHu3V

    Nov. 10, 2017
  • DennisHsiao

    Nov. 9, 2017

附上credit後可分享使用

Views

Total views

5,431

On Slideshare

0

From embeds

0

Number of embeds

3

Actions

Downloads

0

Shares

0

Comments

0

Likes

30

×